Quarterly Result29 Jul 2026, 05:20 pm
Jagsonpal Pharma Declares Q1 FY27 Unaudited Results
AI Summary
Jagsonpal Pharmaceuticals Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company's total income for the quarter stood at ₹850.65 million, a notable increase from ₹673.71 million in the previous quarter (March 31, 2026). Revenue from operations was ₹822.32 million. The Board of Directors approved these results in a meeting held on July 29, 2026. The Limited Review Report was issued by statutory auditors Walker Chandiok & Co LLP, who found no material misstatements.
Key Highlights
- Jagsonpal Pharma reports Q1 FY27 unaudited financial results.
- Total income for Q1 FY27 reached ₹850.65 million.
- Revenue from operations was ₹822.32 million for the quarter.
- Results approved by the Board of Directors on July 29, 2026.
- Statutory auditors issued a Limited Review Report.
Price Impact
More from JAGSNPHARM